BC Week In Review | Dec 22, 2017
Clinical News

TiGenix to discontinue cardiovascular pipeline

TiGenix N.V. (Euronext:TIG; NASDAQ:TIG) said it will discontinue development of its allogeneic cardiovascular stem cell program, including AlloCSC-01, to focus on candidates derived from its expanded adipose-derived stem cell (eASC) platform, including Alofisel darvadstrocel (Cx601)...
BC Week In Review | Feb 16, 2017
Clinical News

Cx611: Ph Ib/IIa SEPCELL started

TiGenix began the double-blind, placebo-controlled, European Phase Ib/IIa SEPCELL trial to evaluate IV Cx611 on days 1 and 3 plus standard of care (SOC) in about 180 patients who have been admitted to intensive care...
BC Week In Review | Mar 23, 2015
Clinical News

Cx611: Phase I data

The open-label, placebo-controlled, Dutch Phase I CELLULA trial in 32 healthy volunteers challenged with a bacterial endotoxin showed that single doses of 250,000, 1,000,000 and 4,000,000 cells/kg IV Cx611 led to no serious adverse events....
BC Week In Review | Jan 5, 2015
Clinical News

Cx611: Phase I started

TiGenix began a placebo-controlled, dose-ranging Phase I trial to evaluate 3 doses of IV Cx611 in about 32 healthy male volunteers challenged with a bacterial endotoxin. TiGenix N.V. (Euronext:TIG), Leuven, Belgium   Product: Cx611  ...
BC Week In Review | Apr 29, 2013
Clinical News

Cx611: Additional Phase IIa data

Pooled data from all 3 dose groups of IV Cx611 (n=46) in a dose-escalation, Spanish Phase IIa trial in 53 patients with RA showed that Cx611 produced an ACR20 response rate of 20%, an ACR50...
BC Week In Review | Jan 7, 2013
Clinical News

Cx611: Interim Phase IIa data

Interim data from a placebo-controlled, dose-escalation, Spanish Phase IIa trial in 53 patients with RA showed that all 3 doses of IV Cx611 were safe with only 2 patients reporting serious adverse events at 3...
BC Week In Review | Aug 13, 2012
Clinical News

Cx611: Completed Phase IIa enrollment

TiGenix completed enrollment of 53 patients in a placebo-controlled, dose-escalation, Spanish Phase IIa trial of Cx611. The company said it expects data from the trial no later than April 2013. TiGenix N.V. (Euronext:TIG), Leuven, Belgium...
BC Week In Review | Apr 23, 2012
Clinical News

Cx611: Phase IIa ongoing

An independent safety monitoring board recommended continuation of the third and final cohort in a placebo-controlled, dose-escalation, Spanish Phase IIa trial of Cx611 based on safety data from the first 3 patients in the cohort....
BC Week In Review | Feb 6, 2012
Clinical News

Cx611: Phase IIa ongoing

An independent safety monitoring board recommended continuation of the second cohort and to open the third and final cohort in a placebo-controlled, dose-escalation, Spanish Phase IIa trial of Cx611 based on safety data from the...
BC Week In Review | Jan 2, 2012
Company News

TiGenix autoimmune, gene/cell therapy news

The REGENER-AR consortium led by TiGenix received a €5.9 million ($7.7 million) grant from the European Commission's Framework Program 7 (FP7) to support development of TiGenix's Cx611 to treat rheumatoid arthritis (RA). TiGenix and its...
Items per page:
1 - 10 of 12